Entities / Company
Compugen Ltd..
publicly traded Israeli drug discovery company
- Reports this week
- 0
- Active events
- 0
- Connections
- 21
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Compugen Ltd. this week
News at the entities that move Compugen Ltd. most-
AstraZeneca StructuralAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Compugen Ltd.
-
Gilead Sciences TransactionalRequired regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Moves Compugen Ltd.
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Compugen Ltd.
Connections
The 5 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Structural
Compugen licenses technology and antibodies to AstraZeneca, enabling the development of the drug Rilvegostomig.
-
Gilead Sciences Transactional
Compugen licensed the drug candidate GS-0321 to Gilead for development following a partnership agreement.
-
Gilead Transactional
Compugen and Gilead engaged in multiple licensing agreements for the GS-0321 antibody.
-
Gilead Transactional
Gilead entered into a licensing agreement with Compugen Ltd. for the technology GS-0321.
-
New York City Shared context
Compugen Ltd. operates within the geographical and professional context of New York City.